INSP: After coding-driven declines in 2026, low-single-digit revenue growth is targeted for 2027

What happened

Inspire Medical's third-quarter revenue fell 7.9% from a year earlier but rose 3% from the prior quarter. Coding and reimbursement challenges were estimated to cut $120 million from full-year 2026 results, and management targets low-single-digit worldwide revenue growth in 2027.

Confirmed

Global impact / market context

The $120 million coding hit shows how billing and reimbursement rules, meaning how insurers agree to pay for procedures, directly reduce revenue for device makers. If spending on growth and battery replacements works, 2027 growth could return, but the 2026 decline pressures profit and investor patience.

Analyst inference

The company is framing 2026 as a coding-driven trough and 2027 as a recovery year. Investors may weigh whether low-single-digit growth justifies current positioning, since a slower rebound would leave revenue below prior levels and could shift expectations for spending and cash available.

Analyst inference

What to watch

1. Watch whether coding stabilizes, since management ties the expected 2027 low-single-digit revenue growth to that stabilization and to contributions from growth investments and battery replacements. Confirmed
2. Track spending on growth investments and battery replacement programs, because management expects these to add revenue; delays or higher costs would affect profit per sale and cash available. Proposed
3. Watch reimbursement decisions, which determine whether procedures get paid. Further coding problems could repeat the $120 million impact, while clearer payment rules would support the 2027 growth target. Analyst inference

Evidence

• Original source link unavailable